Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Anisic Acid SCHEMBL3469544 | 0.88 | CA1 (0.56) | CES2CES1CA1CA2KMT2A | |
| P-Anisic Acid SCHEMBL6586497 | 0.86 | CA1 (0.54) | CES2CES1CA1CA2KMT2A | |
| SCHEMBL27557504 | 0.86 | PARP10 (0.57) | CES2CES1CA1CA2KMT2A | |
| SCHEMBL9240143 | 0.84 | ALDH1A1 (0.40) | CES2CES1CA1CA2KMT2A | |
| 4'-Methoxychalcone SCHEMBL16246379 | 0.78 | MAOB (0.67) | KMT2ANPC1ALDH1A1RAB9ANFKB1 | |
| Anisaldehyde SCHEMBL6586624 | 0.78 | ALDH1A1 (0.54) | KMT2ANPC1ALDH1A1RAB9AHPGD | |
| SCHEMBL10848800 | 0.76 | CES2 (0.50) | CES2CES1CA1CA2KMT2A | |
| SCHEMBL8844457 | 0.76 | SLC6A2 (0.48) | KMT2ANPC1TP53RAB9ASMN1; SMN2 | |
| SCHEMBL27547876 | 0.76 | CES2 (0.50) | CES2CES1KMT2ANPC1ALDH1A1 | |
| SCHEMBL28168223 | 0.76 | APP (0.49) | KMT2ANPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103463086-B | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-10-21 | — | — | CN | disclosed |
| CN-102369194-B | Pyrazolone derivatives and their use as PD4 inhibitors | NYCOMED GMBH | 2014-08-27 | — | — | CN | disclosed |
| CN-103463086-A | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH | 2013-12-25 | — | — | CN | disclosed |
| CN-101657441-B | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH DE | 2013-09-11 | — | — | CN | disclosed |
| CN-102369194-A | Novel pyrazolone derivatives and their use as PD4 inhibitors | NYCOMED GMBH | 2012-03-07 | — | — | CN | disclosed |
| CN-101657441-A | Pyrazolone derivatives as PDE4 inhibitors | NYCOMED GMBH DE | 2010-02-24 | — | — | CN | disclosed |
| CN-1185211-C | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2005-01-19 | — | — | CN | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6498160-B2 | FOR THERAPY OF EMPHYSEMA, CHRONIC BRONCHITIS, ASTHMA AND ALLERGIC RHINITIS | ZAMBON GROUP S.P.A. (IT) | 2002-12-24 | — | — | US | disclosed |
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | ZAMBON GROUP S.P.A. (IT) | 2002-05-16 | — | — | US | disclosed |
| CN-1300278-A | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2001-06-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058662-A1 | Phthalazine derivatives as phosphodiesterase 4 inhibitors | PDE4A, PDE4B, PDE12 | CES2 727/4885CES1 848/4885CA1 3917/4885 |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | CES2 1356/4885CES1 325/4885CA1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.